肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Mol Cancer Ther：GnRH受体靶向抑制剂可联合奥拉帕尼治疗卵巢癌

2019-05-19 QQ MedSci原创

GnRH受体靶向抑制剂EP-100奥拉帕尼卵巢癌
关注

EP-100是一种合成的可溶性多肽，特异性靶向癌细胞上的促性腺激素释放激素受体。为扩大EP-100的应用范围，Shaolin Ma等人尝试探索治疗卵巢癌的EP-100联合方法，并探索这种联合方案的潜在机制。在原位癌的小鼠模型中，EP-100可降低卵巢癌细胞的存活率并抑制肿瘤的生长速度。研究人员还分别检测了EP-100与顺铂、紫杉醇、阿霉素、托泊替康、奥拉帕尼等5种标准药物的联合疗效，发现EP-10

EP-100是一种合成的可溶性多肽，特异性靶向癌细胞上的促性腺激素释放激素受体。为扩大EP-100的应用范围，Shaolin Ma等人尝试探索治疗卵巢癌的EP-100联合方法，并探索这种联合方案的潜在机制。

在原位癌的小鼠模型中，EP-100可降低卵巢癌细胞的存活率并抑制肿瘤的生长速度。研究人员还分别检测了EP-100与顺铂、紫杉醇、阿霉素、托泊替康、奥拉帕尼等5种标准药物的联合疗效，发现EP-100与奥拉帕尼联合应用于卵巢癌细胞系时具有协同抗癌作用。

进一步研究表明EP-100联合奥拉帕尼可显著增加磷酸化组蛋白H2AX的核仁数目。此外，EP-100联合奥拉帕尼处理后，DNA损伤明显增多。研究人员通过反向蛋白阵列分析发现EP-100可抑制PI3K/AKT信号通路，并通过体外实验得到验证。

通过HeyA8 小鼠模型，研究人员发现用EP-100联合奥拉帕尼处理的小鼠的肿瘤重量（0.06±0.13g）要明显轻于安慰剂处理的（1.19±1.09g）、EP-100单独处理的（0.62±0.78g）和奥拉帕尼单独处理的（0.50±0.63g）。

总而言之，本研究提示EP-100联合奥拉帕尼有望成为卵巢癌的有效治疗措施。

原始出处：

Shaolin Ma，et al.GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Molecular Cancer Therapeutics.May 2019.DOI： 10.1158/1535-7163.MCT-18-0770

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819808, encodeId=bb261819808a2, content=<a href='/topic/show?id=338e9990ebe' target=_blank style='color:#2F92EE;'>#靶向抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99907, encryptionId=338e9990ebe, topicName=靶向抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed Sep 04 08:59:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851994, encodeId=95cb1851994cc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 03 07:59:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763332, encodeId=950b1e6333258, content=<a href='/topic/show?id=830281465d' target=_blank style='color:#2F92EE;'>#GnRH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8146, encryptionId=830281465d, topicName=GnRH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4da137488682, createdName=夏天与十三菇凉, createdTime=Thu May 30 06:59:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2019-09-04 villahu

    #靶向抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1819808, encodeId=bb261819808a2, content=<a href='/topic/show?id=338e9990ebe' target=_blank style='color:#2F92EE;'>#靶向抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99907, encryptionId=338e9990ebe, topicName=靶向抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed Sep 04 08:59:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851994, encodeId=95cb1851994cc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 03 07:59:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763332, encodeId=950b1e6333258, content=<a href='/topic/show?id=830281465d' target=_blank style='color:#2F92EE;'>#GnRH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8146, encryptionId=830281465d, topicName=GnRH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4da137488682, createdName=夏天与十三菇凉, createdTime=Thu May 30 06:59:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2019-09-03 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1819808, encodeId=bb261819808a2, content=<a href='/topic/show?id=338e9990ebe' target=_blank style='color:#2F92EE;'>#靶向抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99907, encryptionId=338e9990ebe, topicName=靶向抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Wed Sep 04 08:59:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851994, encodeId=95cb1851994cc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Sep 03 07:59:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763332, encodeId=950b1e6333258, content=<a href='/topic/show?id=830281465d' target=_blank style='color:#2F92EE;'>#GnRH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8146, encryptionId=830281465d, topicName=GnRH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4da137488682, createdName=夏天与十三菇凉, createdTime=Thu May 30 06:59:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2019-05-30 夏天与十三菇凉

    #GnRH#

    0